Chemomab Therapeutics
CMMB
14 hedge funds and large institutions have $4.91M invested in Chemomab Therapeutics in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
21% more capital invested
Capital invested by funds: $4.07M → $4.91M (+$840K)
5.36% more ownership
Funds ownership: 0.25% → 5.61% (+5.4%)
18% less funds holding
Funds holding: 17 → 14 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.85M |
| 2 |
Jane Street
New York
|
+$25.4K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$19.8K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$4.21K |
| 5 |
GI
GAMMA Investing
Foster City,
California
|
+$2.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$990K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$201K |
| 3 |
VF
Virtu Financial
New York
|
-$34K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$24.1K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$14.5K |
CMMB Hedge Fund Activity: Q2 2025 in Review
14 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q2 2025, worth a combined $4.91M — up 21% from $4.07M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CMMB and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Morgan Stanley, adding an estimated $1.85M. The largest seller was OrbiMed, cutting an estimated $990K.
- 14 institutional investors held Chemomab Therapeutics (CMMB) as of Q2 2025, down from 17 in Q1 2025.
- Funds reported $4.91M of Chemomab Therapeutics stock for Q2 2025, up 21% quarter-over-quarter.
- 2 funds opened new Chemomab Therapeutics positions in Q2 2025 and 5 closed out, a net change of -3 holders.
- The largest Chemomab Therapeutics buyer in Q2 2025 was Morgan Stanley, an estimated $1.85M added.
- The largest Chemomab Therapeutics seller in Q2 2025 was OrbiMed, an estimated $990K sold.
Based on aggregated 13F filings for Q2 2025.